Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18405319 | 0.90 | LGMN (0.54) | LGMNMAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL15358734 | 0.87 | MAPT (0.63) | LGMNMAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL2712193 | 0.86 | LGMN (0.62) | LGMNMAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL18405489 | 0.83 | MAPT (0.56) | LGMNMAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL9864307 | 0.83 | MAPT (0.65) | LGMNMAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL904452 | 0.83 | LGMN (0.73) | LGMNMAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL8263576 | 0.80 | MAPT (0.62) | LGMNMAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL22716931 | 0.80 | LGMN (1.00) | LGMNMAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL8060791 | 0.79 | LGMN (0.67) | LGMNMAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL520439 | 0.79 | LGMN (0.67) | LGMNMAPTSMN1; SMN2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1562589-A2 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040214817-A1 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-28 | — | — | US | disclosed |
| WO-2004046120-A2 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-06-03 | — | — | WO | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | LGMN 3373/4885MAPT 2358/4885SMN1; SMN2 2432/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | LGMN 4274/4885MAPT 1323/4885SMN1; SMN2 3050/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | LGMN 4274/4885MAPT 1323/4885SMN1; SMN2 3050/4885 |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | LGMN 1938/4885MAPT 717/4885SMN1; SMN2 2564/4885 |
| US-20040214817-A1 | Diaminotriazoles useful as inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K5 | LGMN 4167/4885MAPT 937/4885SMN1; SMN2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.